Showing results (2231-2240 of 3,026) with videos related to
Sort By:
Pageof 303
Current Pharmaceutical Biotechnology|August 31, 2026
Eco-Friendly Silver Nanoparticles Synthesized from an Alkaloid-Rich Extract of Androcymbium palaestinum: Optimization, Characterization, and Activity Against Antibiotic-Resistant BacteriaNusaiba Al-Nemrawi, Tamam El-Elimat, Alaa Alnaji, et al.Current Pharmaceutical Biotechnology|September 8, 2026
Modeling M. tuberculosis Response to Antibiotics: A Comparison of Logarithmic, Logistic, and Michaelis-Menten ModelsManaf AlMatar, Muna Jalal Ali, Gulfer Yakici, et al.Current Pharmaceutical Biotechnology|July 27, 2001
Antibody-targeted immunotherapy for treatment of non-Hodgkin's lymphomaC A White, J R Berlfein, A J Grillo-LópezCurrent Pharmaceutical Biotechnology|July 27, 2001
Toward the rational design of cell fate modifiers: notch signaling as a target for novel biopharmaceuticalsA Zlobin, M Jang, L MieleCurrent Pharmaceutical Biotechnology|September 4, 2001
Phage displayed biomolecules as preventive and therapeutic agentsK Manoutcharian, G Gevorkian, A Cano, et al.Current Pharmaceutical Biotechnology|July 27, 2001
Biopharmaceutical powders: particle formation and formulation considerationsY F Maa, S J PrestrelskiCurrent Pharmaceutical Biotechnology|January 5, 2002
The history and rationale for monoclonal antibodies in the treatment of hematologic malignancyR O DillmanCurrent Pharmaceutical Biotechnology|January 5, 2002
Antibody therapy of acute and chronic leukemiasS R Cataland, M Lucas, J C ByrdCurrent Pharmaceutical Biotechnology|July 27, 2001
Structure alteration of polyketides by recombinant DNA technology in producer organisms--prospects for the generation of novel pharmaceutical drugsC Méndez, G Weitnauer, A Bechthold, et al.Current Pharmaceutical Biotechnology|July 27, 2001
Inhibition of cellular proliferation by drug targeting of cyclin-dependent kinasesI Pérez-Roger, C Ivorra, A Díez, et al.Pageof 303